Fabrazyme IV 5mg, containing Agalsidase beta (genetically recombinant), is manufactured by Sanofi. This injectable drug, with YJ code 3959409D1029 and standard 5mg x 1 bottle, is an enzyme replacement therapy used in the treatment of Fabry disease.
Fabrazyme IV 5mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →